5-Amino-1MQ
Metabolic (non-peptide) · By Preptide Pro editorial team · Last updated
5-Amino-1MQ is a metabolic (non-peptide) peptide, and it is not FDA-approved. A small-molecule inhibitor of the enzyme NNMT, not a peptide. Research so far is in cells and animals.
Not FDA-approvedChemistry (PubChem)
| PubChem CID | 950107 |
|---|---|
| CAS number | 685079-15-6 |
| Molecular formula | C10H11N2+ |
| Molecular weight | 159.21 g/mol |
| Other names | 5-amino-1-methylquinolinium, 5-AMINO-1-METHYLQUINOLIN-1-IUM, 5-Amino-1-methylquinolinium ion, Quinolinium, 5-amino-1-methyl-, ZMJBCEIHNOWCMC-UHFFFAOYSA-O, STL196667 |
Is 5-Amino-1MQ FDA-approved?
Not FDA-approved. No matching NDA or BLA was found in openFDA (Drugs@FDA).
How much research is there on 5-Amino-1MQ?
PubMed lists 34 records for “5-amino-1MQ OR "NNMT inhibitor"”, of which 0 are tagged as human clinical trials.
| Recent study | Journal | Date |
|---|---|---|
| A Bisubstrate Inhibitor of NNMT Suppresses Myofibroblast Reprogramming to Mitigate Skin Fibrosis. | J Invest Dermatol | 2026 Sep 9 |
| Enhancing glioma immunotherapy by disrupting RBP-J-mediated NNMT signaling in tumor microenvironment. | Oncogene | 2026 Aug |
| Nicotinamide N-Methyltransferase Epigenetically Activates Fibronectin 1 Through H3K9me3 Remodeling in Clear Cell Renal Cell Carcinoma. | MedComm (2020) | 2026 Jul |
| Emerging opportunities for nicotinamide N-methyltransferase (NNMT) inhibitor clinical translation. | Trends Pharmacol Sci | 2026 Jun |
| Nicotinamide N-Methyltransferase Inhibition Mitigates Cerulein-Induced Pancreatic Fibrosis via Galectin-3-Mediated Regulation of Stellate Cell Activation and Macrophage M2 Polarization in Mice. | Inflammation | 2026 Mar 29 |
Sources
This is general research information, not medical advice. Check with a clinician before using any compound.